Pasar al contenido principal

CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Mult Scler Relat Disord.

Enviado por remote_content el

Bass AD, Arroyo R, Boster AL, Boyko AN, Eichau S, Ionete C, Limmroth V, Navas C, Pelletier D, Pozzilli C, Ravenscroft J, Sousa L, Tintoré M, Uitdehaag BMJ, Baker DP, Daizadeh N, Choudhry Z, Rog D; 24/12/2020

Background
Alemtuzumab significantly improved clinical and MRI outcomes vs. subcutaneous interferon beta-1a (SC IFNB-1a) in the CARE-MS trials (NCT00530348, NCT00548405), with sustained efficacy in 2 consecutive extensions (NCT00930553, NCT02255656 [TOPAZ]).

Investigación y educación

Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia. Clin Lymphoma Myeloma Leuk.

Enviado por remote_content el

Combariza JF, Arango M, Díaz L, et al. 14/11/2020

Abstract
Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. The objective of the study was to assess disease-free survival (DFS) and overall survival (OS) of patients with ALL according with MRD status at the end of induction therapy in a Colombian population.

Investigación y educación

Incidence and Prognostic Significance of High-Risk Cytogenetically Abnormalities in Multiple Myeloma Patients in Colombia. Clin Lymphoma Myeloma Leuk.

Enviado por remote_content el

Combariza JF, Ordúz R, Agudelo C, Hernandez S, Madera AM, León G, Avila V,Bautista L, Valdés J, Camargo C, Sanchez V, Mejía F, Moreno L, Ramirez C. 26/02/2022

Investigación y educación